Epidarex Venture Partner Terri Burke will be a featured speaker at Cooley x JLABS @ TMC : Medtech Startup Fundamentals
September 5, 2019
Please click here to view the event’s agenda.
Please click here to view the event’s agenda.
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308),
LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of
Epidarex co-founder and managing partner Kyp Sirinakis has joined TEDCO’s new Task Force for Women Entrepreneurs. The task force is dedicated to the recruitment, funding,
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
Top-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused
Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as
Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM),
Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a